X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1344) 1344
Publication (214) 214
Book Review (16) 16
Magazine Article (10) 10
Book Chapter (9) 9
Newsletter (7) 7
Newspaper Article (6) 6
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1172) 1172
emtricitabine (990) 990
index medicus (903) 903
hiv infections - drug therapy (774) 774
tenofovir (773) 773
anti-hiv agents - therapeutic use (671) 671
male (666) 666
female (632) 632
adult (596) 596
deoxycytidine - analogs & derivatives (546) 546
infectious diseases (546) 546
adenine - analogs & derivatives (505) 505
deoxycytidine - therapeutic use (464) 464
hiv (456) 456
middle aged (411) 411
adenine - therapeutic use (405) 405
human immunodeficiency virus--hiv (363) 363
organophosphonates - therapeutic use (361) 361
pharmacology & pharmacy (312) 312
antiretroviral therapy (301) 301
immunology (273) 273
anti-hiv agents - administration & dosage (271) 271
drug combinations (266) 266
hiv infection (262) 262
drug therapy, combination (258) 258
hiv infections - prevention & control (255) 255
treatment outcome (247) 247
drug therapy (243) 243
hiv infections - virology (236) 236
lamivudine (236) 236
antiretroviral drugs (234) 234
antiviral agents (232) 232
efavirenz (223) 223
hiv-1 - drug effects (218) 218
viral load (213) 213
anti-hiv agents - adverse effects (212) 212
infection (190) 190
tenofovir - therapeutic use (189) 189
microbiology (184) 184
deoxycytidine - administration & dosage (180) 180
adenine - administration & dosage (179) 179
virology (177) 177
lamivudine - therapeutic use (176) 176
reverse transcriptase inhibitors - therapeutic use (174) 174
aids/hiv (173) 173
prevention (173) 173
young adult (173) 173
therapy (168) 168
health aspects (166) 166
acquired immune deficiency syndrome--aids (158) 158
emtricitabine - therapeutic use (157) 157
cd4 lymphocyte count (156) 156
hiv-1 (156) 156
organophosphonates - administration & dosage (156) 156
double-blind (154) 154
tenofovir disoproxil fumarate (146) 146
dosage and administration (144) 144
highly active antiretroviral therapy (134) 134
infections (134) 134
clinical trials (131) 131
pharmacokinetics (131) 131
safety (129) 129
aids (128) 128
research (127) 127
antiviral agents - therapeutic use (124) 124
drug resistance, viral (123) 123
analysis (121) 121
human immunodeficiency virus (118) 118
adenine - adverse effects (116) 116
deoxycytidine - adverse effects (116) 116
disoproxil fumarate (115) 115
medicine (110) 110
adolescent (108) 108
hiv-1 - genetics (108) 108
pre-exposure prophylaxis (108) 108
article (107) 107
efficacy (106) 106
antiretroviral agents (105) 105
hiv infections - complications (105) 105
anti-retroviral agents - therapeutic use (104) 104
organophosphonates - adverse effects (104) 104
drugs (103) 103
abridged index medicus (102) 102
ritonavir - therapeutic use (102) 102
benzoxazines - therapeutic use (101) 101
drug resistance (101) 101
medicine, general & internal (100) 100
research article (99) 99
care and treatment (98) 98
initial treatment (97) 97
mutation (96) 96
patients (96) 96
virus diseases (96) 96
antiretroviral therapy, highly active (95) 95
prophylaxis (95) 95
anti-hiv agents - pharmacology (93) 93
anti-hiv agents - pharmacokinetics (92) 92
drug administration schedule (89) 89
medicine & public health (89) 89
adults (88) 88
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1331) 1331
German (15) 15
Spanish (15) 15
French (10) 10
Japanese (5) 5
Italian (2) 2
Chinese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 6, pp. 1324 - 1334.e3
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity... 
Gastroenterology and Hepatology | Drug Interaction | HCV | Treatment | HIV | Liver Disease | ANTIRETROVIRAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | HUMAN-IMMUNODEFICIENCY-VIRUS | NATURAL-HISTORY | LIVER-DISEASE | SEXUAL TRANSMISSION | HEPATITIS-C VIRUS | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | PEGYLATED INTERFERON-ALPHA-2B | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Coinfection | Antiviral Agents - pharmacokinetics | HIV Infections - epidemiology | Humans | Hepatitis C, Chronic - etiology | Male | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Drug Interactions | Homosexuality, Male | Adenine - therapeutic use | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | Dideoxynucleosides - therapeutic use | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Raltegravir Potassium | Substance Abuse, Intravenous - complications | Emtricitabine | Liver Diseases - virology | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Liver Diseases - prevention & control | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Pyrrolidinones - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Disease Progression | Proline - therapeutic use | HIV Infections - etiology | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Antiviral agents | Medical colleges | Care and treatment | Liver diseases | Comorbidity | Drug interactions | Mortality | Development and progression | Biological response modifiers | HIV (Viruses) | Hepatitis | Protease inhibitors | Proteases | Hepatitis C virus | Hepatitis C | Health aspects | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2013, Volume 62, Issue 5, pp. 483 - 486
Journal Article
AIDS, ISSN 0269-9370, 01/2015, Volume 29, Issue 2, pp. 167 - 174
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Major and Brief Reports
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 08/2006, Volume 26, Issue 8, pp. 1111 - 1133
The human immunodeficiency virus (HIV) was discovered in 1982, but treatment strategies were not introduced until 5 years later. Early regimens consisted of... 
antiretroviral agents | nucleoside reverse transcriptase inhibitors | HIV | human immunodeficiency virus | protease inhibitors | highly active antiretroviral therapy | NRTI | HAART | Highly active antiretroviral therapy | Protease inhibitors | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus | HIV PROTEASE INHIBITORS | COMBINATION THERAPY | REVERSE-TRANSCRIPTASE | EMTRICITABINE | CROSS-RESISTANCE | RANDOMIZED-TRIAL | TENOFOVIR DISOPROXIL FUMARATE | NAIVE PATIENTS | PHARMACOLOGY & PHARMACY | INFECTED PATIENTS | EXPERIENCED PATIENTS | Humans | Organophosphates - therapeutic use | Drugs, Investigational - therapeutic use | Dideoxynucleosides | Reverse Transcriptase Inhibitors - administration & dosage | Oligopeptides - therapeutic use | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | HIV Envelope Protein gp41 - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Anti-Retroviral Agents - therapeutic use | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Clinical Trials as Topic | HIV Protease Inhibitors - administration & dosage | Drug Resistance, Multiple, Viral | HIV Protease Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active | Animals | Sulfonamides - therapeutic use | Anti-Retroviral Agents - administration & dosage | Pyrones - therapeutic use | HIV Infections - drug therapy | Peptide Fragments - therapeutic use | Patient Compliance | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2014, Volume 161, Issue 7, pp. 461 - 471
Journal Article
BMJ Open, ISSN 2044-6055, 09/2017, Volume 7, Issue 9, p. e019022
ObjectiveTo assess the impact of various antiretroviral/antiviral regimens in pregnant women living with HIV or hepatitis B virus (HBV).DesignWe performed... 
chronic hepatitis B | network meta-analysis | tenofovir | HIV & AIDS | pregnancy | mother-to-child transmission | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | INFECTED WOMEN | RANDOMIZED-TRIALS | EFFICACY | VIRUS INFECTION | SAFETY | PREVENT PERINATAL TRANSMISSION | TO-CHILD TRANSMISSION | PREEXPOSURE PROPHYLAXIS | Humans | Infant | Hepatitis B - complications | Lamivudine - adverse effects | Young Adult | Ritonavir - adverse effects | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Female | Anti-Retroviral Agents - therapeutic use | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Zidovudine - adverse effects | Anti-Retroviral Agents - adverse effects | Infectious Disease Transmission, Vertical | Pregnancy | HIV Infections - complications | Hepatitis B - drug therapy | Pregnancy Complications, Infectious - drug therapy | HIV Infections - drug therapy | Lopinavir - therapeutic use | Zidovudine - therapeutic use | Drug Combinations | Lopinavir - adverse effects | Pregnancy Outcome | Low income groups | Antiretroviral drugs | Keywords | Infections | Patients | Evidence-based medicine | Studies | Hepatitis | Acquired immune deficiency syndrome--AIDS | Hepatology | Human immunodeficiency virus--HIV | Medical Subject Headings-MeSH | Drug therapy
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article